Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.49 |
| ▸ | SELL | P14151 | 1/20 | 0.43 |
| ▸ | SELP | P16109 | 1/20 | 0.43 |
| ▸ | YARS1 | P54577 | 1/20 | 0.39 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.36 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | RARB | P10826 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490576 | 0.82 | PTGS2 (0.47) | PTGS2PTGS1LMNACXCR1CXCR2 | |
| SCHEMBL60358 | 0.79 | PTGS2 (0.49) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL490360 | 0.76 | ALDH1A1 (0.42) | LMNAESR1TSHR | |
| SCHEMBL487169 | 0.75 | GABRA1 (0.56) | PTGS1RNASEH1LMNAADRB3TSHR | |
| SCHEMBL9614891 | 0.75 | ADRB2 (0.39) | PTGS1SELLSELPRNASEH1LMNA | |
| SCHEMBL1077644 | 0.75 | PTGS2 (0.40) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL29429345 | 0.73 | TYR (0.55) | PTGS2PTGS1CYP2C9ALOX5TSHR | |
| SCHEMBL490883 | 0.73 | PTGS2 (0.60) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL490490 | 0.73 | TYR (0.55) | PTGS2PTGS1CYP2C9ALOX5TSHR | |
| SCHEMBL6553311 | 0.73 | PTGS2 (0.44) | PTGS2PTGS1LMNACYP2C9AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268293-B2 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| CN-101163659-B | Antioxidants | MERCK PATENT GMBH | 2012-09-05 | — | — | CN | disclosed |
| US-8106233-B2 | Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing | MERCK PATENT GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2008-07-17 | — | — | US | disclosed |
| US-20080152603-A1 | Antioxidants | SUSONITY Commercial GmbH (DE) | 2008-06-26 | — | — | US | disclosed |
| CN-101163659-A | Antioxidants | MERCK PATENT GMBH (DE) | 2008-04-16 | — | — | CN | disclosed |
| EP-1871735-A1 | ANTIOXIDANTS | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| EP-1871339-A1 | UV PROTECTION | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006111233-A1 | ANTIOXIDANTS | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006111234-A1 | UV PROTECTION | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080152603-A1 | Antioxidants | GPX4, GPX1, CAT | PTGS2 320/4885PTGS1 262/4885SELL 2218/4885 |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | HPD, HAAO, UGT1A6 | PTGS2 1873/4885PTGS1 1937/4885SELL 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.